|
|
|
|
LEADER |
00000cam a2200000Mu 4500 |
001 |
EBOOKCENTRAL_ocn908076220 |
003 |
OCoLC |
005 |
20240329122006.0 |
006 |
m o d |
007 |
cr |n||||||||| |
008 |
150509s2002 pau o 000 0 eng d |
040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d YDXCP
|d OCLCQ
|d ZCU
|d MERUC
|d ICG
|d OCLCO
|d OCLCF
|d OCLCQ
|d OCLCO
|d OCLCQ
|d DKC
|d AU@
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
019 |
|
|
|a 923528994
|a 929151885
|
020 |
|
|
|a 9781469877266
|
020 |
|
|
|a 1469877260
|
029 |
1 |
|
|a DEBBG
|b BV044074271
|
035 |
|
|
|a (OCoLC)908076220
|z (OCoLC)923528994
|z (OCoLC)929151885
|
050 |
|
4 |
|a RC374 .C48 A58 2002
|
082 |
0 |
4 |
|a 616.8
|a 616.853061
|
049 |
|
|
|a UAMI
|
100 |
1 |
|
|a Levy, René H.
|
245 |
1 |
0 |
|a Antiepileptic Drugs.
|
250 |
|
|
|a 5th ed.
|
260 |
|
|
|a Philadelphia :
|b Wolters Kluwer Health,
|c 2002.
|
300 |
|
|
|a 1 online resource (987 pages)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
588 |
0 |
|
|a Print version record.
|
505 |
0 |
|
|a Antiepileptic drugs; contents; contributing authors; preface; section i general principles; 1 principles of antiepileptic drug action; 2 neurophysiologic effects of antiepileptic drugs; 3 discovery and preclinical development of antiepileptic drugs; 4 new antiepileptic drug development: medical perspective; 5 clinical development of antiepileptic drugs: industry perspective; 6 the development of antiepileptic drugs: regulatory perspective; 7 antiepileptic drug monotherapy in adults: selection and use in new-onset epilepsy; 8 combination therapy and drug interactions.
|
505 |
8 |
|
|a 9 laboratory monitoring of antiepileptic drugs 10 safety monitoring of antiepileptic drugs; 11 use of antiepileptic drugs in children; 12 antiepileptic drug use in women; 13 epilepsy in the elderly; 14 treatment of status epilepticus; 15 prevention of epileptogenesis; section ii benzodiazepines; 16 mechanisms of action; 17 chemistry, biotransformation, and pharmacokinetics; 18 clinical efficacy and use in epilepsy; 19 adverse effects; section iii carbamazepine; 20 mechanisms of action; 21 chemistry, biotransformation, and pharmacokinetics; 22 interactions with other drugs.
|
505 |
8 |
|
|a 23 clinical efficacy and use in epilepsy24 clinical efficacy and use in other neurologic disorders; 25 clinical efficacy and use in psychiatric disorders; 26 adverse effects; section iv felbamate; 27 felbamate; section v gabapentin; 28 mechanisms of action; 29 chemistry, biotransformation, pharmacokinetics, and interactions; 30 clinical use; 31 clinical efficacy and use in other neurological disorders; 32 clinical efficacy and use in psychiatric disorders; 33 adverse effects; section vi lamotrigine; 34 mechanisms of action; 35 chemistry, biotransformation, and pharmacokinetics.
|
505 |
8 |
|
|a 36 interaction with other drugs37 clinical efficacy and use in epilepsy; 38 efficacy and use in psychiatric disorders; 39 adverse effects; section vii i levetiracetam; 40 mechanisms of action; 41 chemistry, biotransformation, pharmacokinetics, and drug interactions; 42 clinical use; 43 adverse experiences; section viii oxcarbazepine; 44 mechanisms of action; 45 chemistry, biotransformation, and pharmacokinetics; 46 interactions with other drugs; 47 clinical efficacy and use in epilepsy; 48 clinical efficacy and use in psychiatric disorders; 49 adverse effects.
|
505 |
8 |
|
|a Section ix phenobarbital and other barbiturates50 mechanisms of action; 51 chemistry, biotransformation, and pharmacokinetics; 52 interactions with other drugs; 53 clinical efficacy and use in epilepsy; 54 clinical efficacy and use in nonepileptic disorders; 55 adverse effects; 56 methylphenobarbital; section x phenytoin and other hydantoins; 57 mechanisms of action; 58 chemistry and biotransformation; 59 interactions with other drugs; 60 clinical efficacy and use in epilepsy; 61 clinical efficacy and use in other neurological disorders; 62 clinical efficacy and use in psychiatric disorders.
|
500 |
|
|
|a 63 adverse effects.
|
520 |
|
|
|a The thoroughly revised, updated Fifth Edition of this classic is the most comprehensive, current, and authoritative reference on all anticonvulsants available today. This edition features detailed profiles of newer drugs--including levetiracetam, oxcarbazepine, tiagabine, topiramate, and zonisamide--and new chapters on use of antiepileptic drugs in children and during pregnancy. Drugs are covered in alphabetical order and in an easy-to-follow format: mechanisms of action; chemistry, biotransformation, and pharmacokinetics; interactions; clinical efficacy and use; and adverse effects. Coverage.
|
590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
650 |
|
0 |
|a Epilepsy
|x Chemotherapy.
|
650 |
|
0 |
|a Anticonvulsants.
|
650 |
|
2 |
|a Anticonvulsants
|
650 |
|
6 |
|a Anticonvulsivants.
|
650 |
|
7 |
|a Anticonvulsants
|2 fast
|
650 |
|
7 |
|a Epilepsy
|x Chemotherapy
|2 fast
|
700 |
1 |
|
|a Mattson, Richard H.
|
700 |
1 |
|
|a Meldrum, Brian S.
|
758 |
|
|
|i has work:
|a Antiepilptic drugs (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCYTfphkr7RMBdTMTvdp773
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
776 |
0 |
8 |
|i Print version:
|a Levy, René H.
|t Antiepileptic Drugs.
|d Philadelphia : Wolters Kluwer Health, ©2002
|z 9780781723213
|
856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=2032676
|z Texto completo
|
938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL2032676
|
938 |
|
|
|a YBP Library Services
|b YANK
|n 11705178
|
994 |
|
|
|a 92
|b IZTAP
|